|Bid||1.7400 x 800|
|Ask||1.7500 x 1100|
|Day's Range||1.7200 - 1.7600|
|52 Week Range||1.3700 - 8.3800|
|Beta (5Y Monthly)||1.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.10|
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
The analysts covering Surface Oncology, Inc. ( NASDAQ:SURF ) delivered a dose of negativity to shareholders today, by...
If you want to know who really controls Surface Oncology, Inc. ( NASDAQ:SURF ), then you'll have to look at the makeup...
– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim SRF617 clinical data anticipated in the fourth quarter of 2022 – – Multiple clinical readouts anticipated in 1H 2023, including initial safety and efficacy data from SRF388 open-label, lead-in to randomized Phase 2 study in first-line hepatocellular carcinoma (HCC) – – Cash sufficient to fund operations in